🇪🇺 Tygacil in European Union

EMA authorised Tygacil on 24 April 2006

Marketing authorisation

EMA — authorised 24 April 2006

  • Application: EMEA/H/C/000644
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: Tygacil
  • Indication: Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections Complicated intra-abdominal infections (cIAI) Tygacil should be used only in situations where other alternative antibiotics are not suitable. Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.
  • Status: approved

Read official source →

Tygacil in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in European Union

Frequently asked questions

Is Tygacil approved in European Union?

Yes. EMA authorised it on 24 April 2006.

Who is the marketing authorisation holder for Tygacil in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.